also reported that the overexpression of C‐X‐C motif chemokine ligand 1 (CXCL1) in mice liver drive steatosis‐to‐nonalcoholic steatohepatitis (NASH) progression through neutrophil‐derived ROS and activation of stress kinases, and this process could be reversed by IL‐22 treatment. This evidence concerns the gene IL22 and metabolic dysfunction-associated steatohepatitis.